nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—Atenolol—Procarbazine—hematologic cancer	0.223	1	CrCrCtD
Propranolol—ABCB1—hematologic cancer	0.0518	1	CbGaD
Propranolol—SLC22A2—Daunorubicin—hematologic cancer	0.0178	0.0349	CbGbCtD
Propranolol—ORM1—Imatinib—hematologic cancer	0.0165	0.0323	CbGbCtD
Propranolol—SLC22A2—Cytarabine—hematologic cancer	0.0157	0.0308	CbGbCtD
Propranolol—SLC22A2—Cladribine—hematologic cancer	0.0148	0.0291	CbGbCtD
Propranolol—SLC22A2—Imatinib—hematologic cancer	0.0136	0.0267	CbGbCtD
Propranolol—CYP1A2—Anagrelide—hematologic cancer	0.0133	0.0261	CbGbCtD
Propranolol—CYP1A1—Methoxsalen—hematologic cancer	0.0133	0.0261	CbGbCtD
Propranolol—CYP1A1—Bortezomib—hematologic cancer	0.0127	0.0249	CbGbCtD
Propranolol—CYP1A1—Daunorubicin—hematologic cancer	0.0121	0.0238	CbGbCtD
Propranolol—CYP1A1—Thalidomide—hematologic cancer	0.011	0.0217	CbGbCtD
Propranolol—CYP1A1—Dacarbazine—hematologic cancer	0.0095	0.0186	CbGbCtD
Propranolol—ABCB1—Lenalidomide—hematologic cancer	0.00808	0.0158	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Ifosfamide—hematologic cancer	0.00778	0.0153	CbGbCtD
Propranolol—CYP3A7—Ifosfamide—hematologic cancer	0.00778	0.0153	CbGbCtD
Propranolol—SLC22A2—Vinblastine—hematologic cancer	0.00757	0.0148	CbGbCtD
Propranolol—CYP1A1—Dasatinib—hematologic cancer	0.00746	0.0146	CbGbCtD
Propranolol—CYP3A7—Imatinib—hematologic cancer	0.00743	0.0146	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Imatinib—hematologic cancer	0.00743	0.0146	CbGbCtD
Propranolol—CYP3A5—Daunorubicin—hematologic cancer	0.00728	0.0143	CbGbCtD
Propranolol—CYP2D6—Lomustine—hematologic cancer	0.00708	0.0139	CbGbCtD
Propranolol—CYP1A2—Carmustine—hematologic cancer	0.007	0.0137	CbGbCtD
Propranolol—SLC22A2—Cisplatin—hematologic cancer	0.00694	0.0136	CbGbCtD
Propranolol—CYP3A5—Thalidomide—hematologic cancer	0.00663	0.013	CbGbCtD
Propranolol—CYP3A5—Teniposide—hematologic cancer	0.00632	0.0124	CbGbCtD
Propranolol—CYP2D6—Idarubicin—hematologic cancer	0.00631	0.0124	CbGbCtD
Propranolol—CYP2C19—Bortezomib—hematologic cancer	0.00614	0.012	CbGbCtD
Propranolol—CYP1A2—Methoxsalen—hematologic cancer	0.00595	0.0117	CbGbCtD
Propranolol—CYP3A5—Ifosfamide—hematologic cancer	0.00584	0.0114	CbGbCtD
Propranolol—CYP1A2—Bortezomib—hematologic cancer	0.00566	0.0111	CbGbCtD
Propranolol—CYP3A5—Imatinib—hematologic cancer	0.00557	0.0109	CbGbCtD
Propranolol—CYP1A2—Daunorubicin—hematologic cancer	0.00542	0.0106	CbGbCtD
Propranolol—CYP2D6—Hydroxyurea—hematologic cancer	0.00536	0.0105	CbGbCtD
Propranolol—CYP2C19—Thalidomide—hematologic cancer	0.00535	0.0105	CbGbCtD
Propranolol—CYP1A2—Alitretinoin—hematologic cancer	0.00531	0.0104	CbGbCtD
Propranolol—CYP2C19—Teniposide—hematologic cancer	0.0051	0.01	CbGbCtD
Propranolol—CYP1A2—Thalidomide—hematologic cancer	0.00493	0.00968	CbGbCtD
Propranolol—CYP3A4—Bexarotene—hematologic cancer	0.00484	0.0095	CbGbCtD
Propranolol—ABCB1—Daunorubicin—hematologic cancer	0.00474	0.00929	CbGbCtD
Propranolol—CYP2C19—Ifosfamide—hematologic cancer	0.00471	0.00923	CbGbCtD
Propranolol—CYP2D6—Bortezomib—hematologic cancer	0.00467	0.00915	CbGbCtD
Propranolol—CYP3A7—Irinotecan—hematologic cancer	0.00464	0.00911	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Irinotecan—hematologic cancer	0.00464	0.00911	CbGbCtD
Propranolol—ABCB1—Alitretinoin—hematologic cancer	0.00464	0.0091	CbGbCtD
Propranolol—CYP3A4—Lomustine—hematologic cancer	0.0045	0.00883	CbGbCtD
Propranolol—CYP3A4—Busulfan—hematologic cancer	0.0045	0.00883	CbGbCtD
Propranolol—CYP2C19—Imatinib—hematologic cancer	0.0045	0.00882	CbGbCtD
Propranolol—CYP3A5—Dasatinib—hematologic cancer	0.00448	0.00878	CbGbCtD
Propranolol—CYP1A2—Dacarbazine—hematologic cancer	0.00424	0.00832	CbGbCtD
Propranolol—CYP1A2—Imatinib—hematologic cancer	0.00415	0.00814	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Vincristine—hematologic cancer	0.00406	0.00796	CbGbCtD
Propranolol—CYP3A7—Vincristine—hematologic cancer	0.00406	0.00796	CbGbCtD
Propranolol—CYP3A4—Thiotepa—hematologic cancer	0.00401	0.00787	CbGbCtD
Propranolol—CYP1A1—Dexamethasone—hematologic cancer	0.00382	0.00749	CbGbCtD
Propranolol—ABCB1—Imatinib—hematologic cancer	0.00363	0.00712	CbGbCtD
Propranolol—CYP3A5—Irinotecan—hematologic cancer	0.00348	0.00683	CbGbCtD
Propranolol—CYP2D6—Imatinib—hematologic cancer	0.00342	0.00671	CbGbCtD
Propranolol—CYP1A2—Dasatinib—hematologic cancer	0.00333	0.00654	CbGbCtD
Propranolol—ABCB1—Nilotinib—hematologic cancer	0.0033	0.00647	CbGbCtD
Propranolol—ABCB1—Vinorelbine—hematologic cancer	0.00327	0.00641	CbGbCtD
Propranolol—CYP3A4—Methoxsalen—hematologic cancer	0.00312	0.00612	CbGbCtD
Propranolol—CYP2D6—Nilotinib—hematologic cancer	0.00311	0.00609	CbGbCtD
Propranolol—CYP2D6—Vinorelbine—hematologic cancer	0.00308	0.00604	CbGbCtD
Propranolol—CYP3A7—Dexamethasone—hematologic cancer	0.00306	0.006	CbGbCtD
Propranolol—CYP3A7-CYP3A51P—Dexamethasone—hematologic cancer	0.00306	0.006	CbGbCtD
Propranolol—CYP3A5—Vincristine—hematologic cancer	0.00304	0.00597	CbGbCtD
Propranolol—CYP3A4—Bortezomib—hematologic cancer	0.00297	0.00582	CbGbCtD
Propranolol—CYP2C19—Prednisone—hematologic cancer	0.00296	0.00581	CbGbCtD
Propranolol—ABCB1—Dasatinib—hematologic cancer	0.00291	0.00572	CbGbCtD
Propranolol—ABCB1—Mitoxantrone—hematologic cancer	0.00288	0.00565	CbGbCtD
Propranolol—CYP3A4—Daunorubicin—hematologic cancer	0.00284	0.00557	CbGbCtD
Propranolol—CYP3A5—Etoposide—hematologic cancer	0.00279	0.00547	CbGbCtD
Propranolol—ABCB1—Betamethasone—hematologic cancer	0.00257	0.00503	CbGbCtD
Propranolol—ABCB1—Gemcitabine—hematologic cancer	0.00254	0.00499	CbGbCtD
Propranolol—ABCB1—Prednisolone—hematologic cancer	0.00253	0.00497	CbGbCtD
Propranolol—CYP3A4—Cytarabine—hematologic cancer	0.0025	0.00491	CbGbCtD
Propranolol—CYP3A4—Teniposide—hematologic cancer	0.00247	0.00484	CbGbCtD
Propranolol—ABCB1—Prednisone—hematologic cancer	0.00239	0.00469	CbGbCtD
Propranolol—CYP3A5—Dexamethasone—hematologic cancer	0.00229	0.0045	CbGbCtD
Propranolol—CYP3A4—Ifosfamide—hematologic cancer	0.00228	0.00446	CbGbCtD
Propranolol—ABCB1—Irinotecan—hematologic cancer	0.00227	0.00445	CbGbCtD
Propranolol—CYP3A4—Imatinib—hematologic cancer	0.00217	0.00426	CbGbCtD
Propranolol—CYP1A2—Etoposide—hematologic cancer	0.00208	0.00407	CbGbCtD
Propranolol—CYP3A4—Ruxolitinib—hematologic cancer	0.00205	0.00402	CbGbCtD
Propranolol—ABCB1—Vinblastine—hematologic cancer	0.00201	0.00395	CbGbCtD
Propranolol—ABCB1—Vincristine—hematologic cancer	0.00198	0.00389	CbGbCtD
Propranolol—CYP3A4—Nilotinib—hematologic cancer	0.00198	0.00388	CbGbCtD
Propranolol—CYP3A4—Vinorelbine—hematologic cancer	0.00196	0.00384	CbGbCtD
Propranolol—CYP2D6—Vinblastine—hematologic cancer	0.0019	0.00372	CbGbCtD
Propranolol—CYP2C19—Dexamethasone—hematologic cancer	0.00185	0.00363	CbGbCtD
Propranolol—ABCB1—Cisplatin—hematologic cancer	0.00185	0.00362	CbGbCtD
Propranolol—ABCB1—Etoposide—hematologic cancer	0.00182	0.00356	CbGbCtD
Propranolol—CYP3A4—Triamcinolone—hematologic cancer	0.00179	0.00351	CbGbCtD
Propranolol—CYP3A4—Dasatinib—hematologic cancer	0.00175	0.00343	CbGbCtD
Propranolol—CYP3A4—Mitoxantrone—hematologic cancer	0.00172	0.00338	CbGbCtD
Propranolol—CYP3A4—Betamethasone—hematologic cancer	0.00154	0.00302	CbGbCtD
Propranolol—CYP3A4—Prednisolone—hematologic cancer	0.00152	0.00298	CbGbCtD
Propranolol—ABCB1—Dexamethasone—hematologic cancer	0.00149	0.00293	CbGbCtD
Propranolol—CYP3A4—Prednisone—hematologic cancer	0.00143	0.00281	CbGbCtD
Propranolol—CYP2D6—Dexamethasone—hematologic cancer	0.00141	0.00276	CbGbCtD
Propranolol—CYP3A4—Irinotecan—hematologic cancer	0.00136	0.00266	CbGbCtD
Propranolol—ABCB1—Doxorubicin—hematologic cancer	0.00124	0.00243	CbGbCtD
Propranolol—CYP3A4—Vinblastine—hematologic cancer	0.00121	0.00237	CbGbCtD
Propranolol—ABCB1—Methotrexate—hematologic cancer	0.0012	0.00235	CbGbCtD
Propranolol—CYP3A4—Vincristine—hematologic cancer	0.00119	0.00233	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—hematologic cancer	0.00117	0.00229	CbGbCtD
Propranolol—CYP3A4—Etoposide—hematologic cancer	0.00109	0.00213	CbGbCtD
Propranolol—CYP3A4—Dexamethasone—hematologic cancer	0.000894	0.00175	CbGbCtD
Propranolol—CYP3A4—Doxorubicin—hematologic cancer	0.000742	0.00146	CbGbCtD
Propranolol—Acebutolol—SLC22A1—hematologic cancer	0.000207	0.353	CrCbGaD
Propranolol—Carvedilol—VEGFA—hematologic cancer	0.000132	0.224	CrCbGaD
Propranolol—ORM1—hematopoietic system—hematologic cancer	7.19e-05	0.0786	CbGeAlD
Propranolol—Atenolol—ABCB1—hematologic cancer	6.53e-05	0.111	CrCbGaD
Propranolol—Acebutolol—ABCB1—hematologic cancer	6.02e-05	0.103	CrCbGaD
Propranolol—HTR1A—hematopoietic system—hematologic cancer	5.44e-05	0.0594	CbGeAlD
Propranolol—Metoprolol—ABCB1—hematologic cancer	5.09e-05	0.0867	CrCbGaD
Propranolol—CYP2C19—hematopoietic system—hematologic cancer	5.08e-05	0.0555	CbGeAlD
Propranolol—ORM1—blood—hematologic cancer	4.77e-05	0.0521	CbGeAlD
Propranolol—ORM1—bone marrow—hematologic cancer	4.61e-05	0.0504	CbGeAlD
Propranolol—ORM1—lung—hematologic cancer	4.18e-05	0.0456	CbGeAlD
Propranolol—CYP1A2—hematopoietic system—hematologic cancer	4.15e-05	0.0453	CbGeAlD
Propranolol—CYP1A1—hematopoietic system—hematologic cancer	4.09e-05	0.0447	CbGeAlD
Propranolol—CYP3A5—hematopoietic system—hematologic cancer	4e-05	0.0437	CbGeAlD
Propranolol—Propafenone—ABCB1—hematologic cancer	3.75e-05	0.0639	CrCbGaD
Propranolol—ADRB1—lung—hematologic cancer	3.69e-05	0.0402	CbGeAlD
Propranolol—Carvedilol—ABCB1—hematologic cancer	3.38e-05	0.0576	CrCbGaD
Propranolol—CYP2C19—blood—hematologic cancer	3.37e-05	0.0368	CbGeAlD
Propranolol—Dizziness—Vincristine—hematologic cancer	3.25e-05	0.000206	CcSEcCtD
Propranolol—Rash—Carmustine—hematologic cancer	3.25e-05	0.000206	CcSEcCtD
Propranolol—Dermatitis—Carmustine—hematologic cancer	3.25e-05	0.000206	CcSEcCtD
Propranolol—Vomiting—Alitretinoin—hematologic cancer	3.25e-05	0.000206	CcSEcCtD
Propranolol—Paraesthesia—Triamcinolone—hematologic cancer	3.25e-05	0.000206	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—hematologic cancer	3.24e-05	0.000205	CcSEcCtD
Propranolol—Infestation—Doxorubicin—hematologic cancer	3.24e-05	0.000205	CcSEcCtD
Propranolol—Visual impairment—Methotrexate—hematologic cancer	3.24e-05	0.000205	CcSEcCtD
Propranolol—Dyspnoea—Triamcinolone—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Rash—Alitretinoin—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Nervous system disorder—Dexamethasone—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Nervous system disorder—Betamethasone—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Agitation—Prednisone—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Dermatitis—Alitretinoin—hematologic cancer	3.22e-05	0.000204	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—hematologic cancer	3.21e-05	0.000204	CcSEcCtD
Propranolol—Vomiting—Ifosfamide—hematologic cancer	3.21e-05	0.000203	CcSEcCtD
Propranolol—Hypersensitivity—Cisplatin—hematologic cancer	3.21e-05	0.000203	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—hematologic cancer	3.2e-05	0.000203	CcSEcCtD
Propranolol—Diarrhoea—Gemcitabine—hematologic cancer	3.19e-05	0.000202	CcSEcCtD
Propranolol—Nausea—Thalidomide—hematologic cancer	3.19e-05	0.000202	CcSEcCtD
Propranolol—Dyspepsia—Triamcinolone—hematologic cancer	3.18e-05	0.000202	CcSEcCtD
Propranolol—Rash—Ifosfamide—hematologic cancer	3.18e-05	0.000202	CcSEcCtD
Propranolol—Dermatitis—Ifosfamide—hematologic cancer	3.18e-05	0.000201	CcSEcCtD
Propranolol—Erythema multiforme—Methotrexate—hematologic cancer	3.18e-05	0.000201	CcSEcCtD
Propranolol—Dizziness—Irinotecan—hematologic cancer	3.17e-05	0.000201	CcSEcCtD
Propranolol—Urticaria—Etoposide—hematologic cancer	3.17e-05	0.000201	CcSEcCtD
Propranolol—Body temperature increased—Etoposide—hematologic cancer	3.15e-05	0.0002	CcSEcCtD
Propranolol—Abdominal pain—Etoposide—hematologic cancer	3.15e-05	0.0002	CcSEcCtD
Propranolol—Vertigo—Prednisone—hematologic cancer	3.15e-05	0.000199	CcSEcCtD
Propranolol—Vomiting—Vincristine—hematologic cancer	3.13e-05	0.000198	CcSEcCtD
Propranolol—Urticaria—Prednisolone—hematologic cancer	3.12e-05	0.000198	CcSEcCtD
Propranolol—Asthenia—Cisplatin—hematologic cancer	3.12e-05	0.000198	CcSEcCtD
Propranolol—Pharyngitis—Epirubicin—hematologic cancer	3.12e-05	0.000198	CcSEcCtD
Propranolol—Cardiac disorder—Methotrexate—hematologic cancer	3.12e-05	0.000198	CcSEcCtD
Propranolol—Fatigue—Triamcinolone—hematologic cancer	3.12e-05	0.000198	CcSEcCtD
Propranolol—Rash—Vincristine—hematologic cancer	3.1e-05	0.000197	CcSEcCtD
Propranolol—Dermatitis—Vincristine—hematologic cancer	3.1e-05	0.000196	CcSEcCtD
Propranolol—Pain—Triamcinolone—hematologic cancer	3.09e-05	0.000196	CcSEcCtD
Propranolol—Nausea—Carmustine—hematologic cancer	3.06e-05	0.000194	CcSEcCtD
Propranolol—Vomiting—Mitoxantrone—hematologic cancer	3.05e-05	0.000193	CcSEcCtD
Propranolol—Vomiting—Irinotecan—hematologic cancer	3.05e-05	0.000193	CcSEcCtD
Propranolol—Nausea—Alitretinoin—hematologic cancer	3.03e-05	0.000192	CcSEcCtD
Propranolol—Convulsion—Prednisone—hematologic cancer	3.03e-05	0.000192	CcSEcCtD
Propranolol—Visual impairment—Epirubicin—hematologic cancer	3.03e-05	0.000192	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—hematologic cancer	3.03e-05	0.000192	CcSEcCtD
Propranolol—Rash—Mitoxantrone—hematologic cancer	3.02e-05	0.000191	CcSEcCtD
Propranolol—Rash—Irinotecan—hematologic cancer	3.02e-05	0.000191	CcSEcCtD
Propranolol—Dermatitis—Mitoxantrone—hematologic cancer	3.02e-05	0.000191	CcSEcCtD
Propranolol—Dermatitis—Irinotecan—hematologic cancer	3.02e-05	0.000191	CcSEcCtD
Propranolol—CYP3A4—hematopoietic system—hematologic cancer	3e-05	0.0328	CbGeAlD
Propranolol—Nausea—Ifosfamide—hematologic cancer	3e-05	0.00019	CcSEcCtD
Propranolol—Diarrhoea—Cisplatin—hematologic cancer	2.98e-05	0.000189	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—hematologic cancer	2.97e-05	0.000188	CcSEcCtD
Propranolol—Alopecia—Methotrexate—hematologic cancer	2.97e-05	0.000188	CcSEcCtD
Propranolol—Vomiting—Gemcitabine—hematologic cancer	2.97e-05	0.000188	CcSEcCtD
Propranolol—Insomnia—Dexamethasone—hematologic cancer	2.97e-05	0.000188	CcSEcCtD
Propranolol—Insomnia—Betamethasone—hematologic cancer	2.97e-05	0.000188	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—hematologic cancer	2.96e-05	0.000188	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	2.96e-05	0.000188	CcSEcCtD
Propranolol—CYP2D6—hematopoietic system—hematologic cancer	2.95e-05	0.0323	CbGeAlD
Propranolol—Paraesthesia—Betamethasone—hematologic cancer	2.95e-05	0.000187	CcSEcCtD
Propranolol—Paraesthesia—Dexamethasone—hematologic cancer	2.95e-05	0.000187	CcSEcCtD
Propranolol—Mental disorder—Methotrexate—hematologic cancer	2.94e-05	0.000187	CcSEcCtD
Propranolol—Rash—Gemcitabine—hematologic cancer	2.94e-05	0.000187	CcSEcCtD
Propranolol—Dermatitis—Gemcitabine—hematologic cancer	2.94e-05	0.000186	CcSEcCtD
Propranolol—Hypersensitivity—Etoposide—hematologic cancer	2.94e-05	0.000186	CcSEcCtD
Propranolol—Erythema—Methotrexate—hematologic cancer	2.93e-05	0.000185	CcSEcCtD
Propranolol—Nausea—Vincristine—hematologic cancer	2.92e-05	0.000185	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—hematologic cancer	2.92e-05	0.000185	CcSEcCtD
Propranolol—Hypersensitivity—Prednisolone—hematologic cancer	2.9e-05	0.000184	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—hematologic cancer	2.89e-05	0.000183	CcSEcCtD
Propranolol—Dyspepsia—Betamethasone—hematologic cancer	2.89e-05	0.000183	CcSEcCtD
Propranolol—Dyspepsia—Dexamethasone—hematologic cancer	2.89e-05	0.000183	CcSEcCtD
Propranolol—Urticaria—Triamcinolone—hematologic cancer	2.87e-05	0.000182	CcSEcCtD
Propranolol—Asthenia—Etoposide—hematologic cancer	2.86e-05	0.000181	CcSEcCtD
Propranolol—Body temperature increased—Triamcinolone—hematologic cancer	2.86e-05	0.000181	CcSEcCtD
Propranolol—ORM1—lymph node—hematologic cancer	2.86e-05	0.0312	CbGeAlD
Propranolol—Anaphylactic shock—Prednisone—hematologic cancer	2.86e-05	0.000181	CcSEcCtD
Propranolol—Decreased appetite—Dexamethasone—hematologic cancer	2.85e-05	0.000181	CcSEcCtD
Propranolol—Decreased appetite—Betamethasone—hematologic cancer	2.85e-05	0.000181	CcSEcCtD
Propranolol—Nausea—Mitoxantrone—hematologic cancer	2.85e-05	0.00018	CcSEcCtD
Propranolol—Nausea—Irinotecan—hematologic cancer	2.85e-05	0.00018	CcSEcCtD
Propranolol—Infection—Prednisone—hematologic cancer	2.84e-05	0.00018	CcSEcCtD
Propranolol—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.83e-05	0.000179	CcSEcCtD
Propranolol—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.83e-05	0.000179	CcSEcCtD
Propranolol—Fatigue—Betamethasone—hematologic cancer	2.83e-05	0.000179	CcSEcCtD
Propranolol—Fatigue—Dexamethasone—hematologic cancer	2.83e-05	0.000179	CcSEcCtD
Propranolol—Pain—Betamethasone—hematologic cancer	2.81e-05	0.000178	CcSEcCtD
Propranolol—Pain—Dexamethasone—hematologic cancer	2.81e-05	0.000178	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—hematologic cancer	2.8e-05	0.000178	CcSEcCtD
Propranolol—Nervous system disorder—Prednisone—hematologic cancer	2.8e-05	0.000178	CcSEcCtD
Propranolol—Alopecia—Epirubicin—hematologic cancer	2.78e-05	0.000176	CcSEcCtD
Propranolol—Skin disorder—Prednisone—hematologic cancer	2.78e-05	0.000176	CcSEcCtD
Propranolol—Nausea—Gemcitabine—hematologic cancer	2.77e-05	0.000176	CcSEcCtD
Propranolol—Vomiting—Cisplatin—hematologic cancer	2.77e-05	0.000175	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—hematologic cancer	2.76e-05	0.000175	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—hematologic cancer	2.75e-05	0.000174	CcSEcCtD
Propranolol—CYP1A2—blood—hematologic cancer	2.75e-05	0.03	CbGeAlD
Propranolol—Rash—Cisplatin—hematologic cancer	2.74e-05	0.000174	CcSEcCtD
Propranolol—Dermatitis—Cisplatin—hematologic cancer	2.74e-05	0.000174	CcSEcCtD
Propranolol—Erythema—Epirubicin—hematologic cancer	2.74e-05	0.000173	CcSEcCtD
Propranolol—Diarrhoea—Etoposide—hematologic cancer	2.73e-05	0.000173	CcSEcCtD
Propranolol—CYP1A1—blood—hematologic cancer	2.71e-05	0.0296	CbGeAlD
Propranolol—Cardiac disorder—Doxorubicin—hematologic cancer	2.7e-05	0.000171	CcSEcCtD
Propranolol—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.68e-05	0.00017	CcSEcCtD
Propranolol—Gastrointestinal pain—Betamethasone—hematologic cancer	2.68e-05	0.00017	CcSEcCtD
Propranolol—Hypersensitivity—Triamcinolone—hematologic cancer	2.66e-05	0.000169	CcSEcCtD
Propranolol—CYP3A5—blood—hematologic cancer	2.65e-05	0.029	CbGeAlD
Propranolol—Dizziness—Etoposide—hematologic cancer	2.64e-05	0.000167	CcSEcCtD
Propranolol—Vertigo—Methotrexate—hematologic cancer	2.63e-05	0.000167	CcSEcCtD
Propranolol—Urticaria—Betamethasone—hematologic cancer	2.61e-05	0.000165	CcSEcCtD
Propranolol—Urticaria—Dexamethasone—hematologic cancer	2.61e-05	0.000165	CcSEcCtD
Propranolol—Dizziness—Prednisolone—hematologic cancer	2.6e-05	0.000165	CcSEcCtD
Propranolol—Asthenia—Triamcinolone—hematologic cancer	2.59e-05	0.000164	CcSEcCtD
Propranolol—Abdominal pain—Betamethasone—hematologic cancer	2.59e-05	0.000164	CcSEcCtD
Propranolol—Body temperature increased—Dexamethasone—hematologic cancer	2.59e-05	0.000164	CcSEcCtD
Propranolol—Abdominal pain—Dexamethasone—hematologic cancer	2.59e-05	0.000164	CcSEcCtD
Propranolol—Body temperature increased—Betamethasone—hematologic cancer	2.59e-05	0.000164	CcSEcCtD
Propranolol—Nausea—Cisplatin—hematologic cancer	2.58e-05	0.000164	CcSEcCtD
Propranolol—Insomnia—Prednisone—hematologic cancer	2.58e-05	0.000164	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—hematologic cancer	2.57e-05	0.000163	CcSEcCtD
Propranolol—Paraesthesia—Prednisone—hematologic cancer	2.57e-05	0.000163	CcSEcCtD
Propranolol—Cough—Methotrexate—hematologic cancer	2.55e-05	0.000162	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—hematologic cancer	2.55e-05	0.000162	CcSEcCtD
Propranolol—Convulsion—Methotrexate—hematologic cancer	2.53e-05	0.000161	CcSEcCtD
Propranolol—Vomiting—Etoposide—hematologic cancer	2.53e-05	0.000161	CcSEcCtD
Propranolol—Erythema—Doxorubicin—hematologic cancer	2.53e-05	0.000161	CcSEcCtD
Propranolol—Agitation—Epirubicin—hematologic cancer	2.52e-05	0.000159	CcSEcCtD
Propranolol—Dyspepsia—Prednisone—hematologic cancer	2.51e-05	0.000159	CcSEcCtD
Propranolol—Rash—Etoposide—hematologic cancer	2.51e-05	0.000159	CcSEcCtD
Propranolol—Dermatitis—Etoposide—hematologic cancer	2.51e-05	0.000159	CcSEcCtD
Propranolol—Decreased appetite—Prednisone—hematologic cancer	2.48e-05	0.000157	CcSEcCtD
Propranolol—Rash—Prednisolone—hematologic cancer	2.48e-05	0.000157	CcSEcCtD
Propranolol—Dermatitis—Prednisolone—hematologic cancer	2.48e-05	0.000157	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.47e-05	0.000157	CcSEcCtD
Propranolol—Fatigue—Prednisone—hematologic cancer	2.46e-05	0.000156	CcSEcCtD
Propranolol—Vertigo—Epirubicin—hematologic cancer	2.46e-05	0.000156	CcSEcCtD
Propranolol—Constipation—Prednisone—hematologic cancer	2.44e-05	0.000155	CcSEcCtD
Propranolol—CYP1A2—lung—hematologic cancer	2.41e-05	0.0263	CbGeAlD
Propranolol—Dizziness—Triamcinolone—hematologic cancer	2.39e-05	0.000151	CcSEcCtD
Propranolol—Cough—Epirubicin—hematologic cancer	2.39e-05	0.000151	CcSEcCtD
Propranolol—Anaphylactic shock—Methotrexate—hematologic cancer	2.39e-05	0.000151	CcSEcCtD
Propranolol—CYP1A1—lung—hematologic cancer	2.38e-05	0.026	CbGeAlD
Propranolol—Convulsion—Epirubicin—hematologic cancer	2.37e-05	0.00015	CcSEcCtD
Propranolol—Infection—Methotrexate—hematologic cancer	2.37e-05	0.00015	CcSEcCtD
Propranolol—Nausea—Etoposide—hematologic cancer	2.37e-05	0.00015	CcSEcCtD
Propranolol—Asthenia—Dexamethasone—hematologic cancer	2.35e-05	0.000149	CcSEcCtD
Propranolol—Asthenia—Betamethasone—hematologic cancer	2.35e-05	0.000149	CcSEcCtD
Propranolol—Nervous system disorder—Methotrexate—hematologic cancer	2.34e-05	0.000148	CcSEcCtD
Propranolol—Gastrointestinal pain—Prednisone—hematologic cancer	2.34e-05	0.000148	CcSEcCtD
Propranolol—Nausea—Prednisolone—hematologic cancer	2.34e-05	0.000148	CcSEcCtD
Propranolol—Agitation—Doxorubicin—hematologic cancer	2.33e-05	0.000148	CcSEcCtD
Propranolol—CYP3A5—lung—hematologic cancer	2.32e-05	0.0254	CbGeAlD
Propranolol—Skin disorder—Methotrexate—hematologic cancer	2.32e-05	0.000147	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.31e-05	0.000147	CcSEcCtD
Propranolol—Vomiting—Triamcinolone—hematologic cancer	2.3e-05	0.000146	CcSEcCtD
Propranolol—Rash—Triamcinolone—hematologic cancer	2.28e-05	0.000144	CcSEcCtD
Propranolol—Dermatitis—Triamcinolone—hematologic cancer	2.28e-05	0.000144	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—hematologic cancer	2.28e-05	0.000144	CcSEcCtD
Propranolol—Urticaria—Prednisone—hematologic cancer	2.27e-05	0.000144	CcSEcCtD
Propranolol—Abdominal pain—Prednisone—hematologic cancer	2.26e-05	0.000143	CcSEcCtD
Propranolol—Body temperature increased—Prednisone—hematologic cancer	2.26e-05	0.000143	CcSEcCtD
Propranolol—Diarrhoea—Betamethasone—hematologic cancer	2.24e-05	0.000142	CcSEcCtD
Propranolol—Diarrhoea—Dexamethasone—hematologic cancer	2.24e-05	0.000142	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—hematologic cancer	2.23e-05	0.000142	CcSEcCtD
Propranolol—Infection—Epirubicin—hematologic cancer	2.22e-05	0.000141	CcSEcCtD
Propranolol—Cough—Doxorubicin—hematologic cancer	2.21e-05	0.00014	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—hematologic cancer	2.19e-05	0.000139	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—hematologic cancer	2.19e-05	0.000139	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—hematologic cancer	2.17e-05	0.000138	CcSEcCtD
Propranolol—Dizziness—Betamethasone—hematologic cancer	2.17e-05	0.000137	CcSEcCtD
Propranolol—Dizziness—Dexamethasone—hematologic cancer	2.17e-05	0.000137	CcSEcCtD
Propranolol—Insomnia—Methotrexate—hematologic cancer	2.16e-05	0.000137	CcSEcCtD
Propranolol—Nausea—Triamcinolone—hematologic cancer	2.15e-05	0.000136	CcSEcCtD
Propranolol—Paraesthesia—Methotrexate—hematologic cancer	2.14e-05	0.000136	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.14e-05	0.000136	CcSEcCtD
Propranolol—Dyspnoea—Methotrexate—hematologic cancer	2.13e-05	0.000135	CcSEcCtD
Propranolol—ABCB1—hematopoietic system—hematologic cancer	2.13e-05	0.0232	CbGeAlD
Propranolol—Somnolence—Methotrexate—hematologic cancer	2.12e-05	0.000134	CcSEcCtD
Propranolol—Hypersensitivity—Prednisone—hematologic cancer	2.1e-05	0.000133	CcSEcCtD
Propranolol—Dyspepsia—Methotrexate—hematologic cancer	2.1e-05	0.000133	CcSEcCtD
Propranolol—Vomiting—Dexamethasone—hematologic cancer	2.09e-05	0.000132	CcSEcCtD
Propranolol—Vomiting—Betamethasone—hematologic cancer	2.09e-05	0.000132	CcSEcCtD
Propranolol—Decreased appetite—Methotrexate—hematologic cancer	2.08e-05	0.000132	CcSEcCtD
Propranolol—Rash—Dexamethasone—hematologic cancer	2.07e-05	0.000131	CcSEcCtD
Propranolol—Rash—Betamethasone—hematologic cancer	2.07e-05	0.000131	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—hematologic cancer	2.07e-05	0.000131	CcSEcCtD
Propranolol—Dermatitis—Betamethasone—hematologic cancer	2.07e-05	0.000131	CcSEcCtD
Propranolol—Dermatitis—Dexamethasone—hematologic cancer	2.07e-05	0.000131	CcSEcCtD
Propranolol—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.06e-05	0.000131	CcSEcCtD
Propranolol—Fatigue—Methotrexate—hematologic cancer	2.06e-05	0.00013	CcSEcCtD
Propranolol—Infection—Doxorubicin—hematologic cancer	2.05e-05	0.00013	CcSEcCtD
Propranolol—Asthenia—Prednisone—hematologic cancer	2.05e-05	0.00013	CcSEcCtD
Propranolol—Pain—Methotrexate—hematologic cancer	2.04e-05	0.000129	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—hematologic cancer	2.03e-05	0.000128	CcSEcCtD
Propranolol—Insomnia—Epirubicin—hematologic cancer	2.02e-05	0.000128	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—hematologic cancer	2.01e-05	0.000127	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—hematologic cancer	2.01e-05	0.000127	CcSEcCtD
Propranolol—Dyspnoea—Epirubicin—hematologic cancer	1.99e-05	0.000126	CcSEcCtD
Propranolol—CYP3A4—blood—hematologic cancer	1.99e-05	0.0217	CbGeAlD
Propranolol—Somnolence—Epirubicin—hematologic cancer	1.99e-05	0.000126	CcSEcCtD
Propranolol—Dyspepsia—Epirubicin—hematologic cancer	1.97e-05	0.000125	CcSEcCtD
Propranolol—CYP2D6—blood—hematologic cancer	1.96e-05	0.0214	CbGeAlD
Propranolol—Diarrhoea—Prednisone—hematologic cancer	1.95e-05	0.000124	CcSEcCtD
Propranolol—Gastrointestinal pain—Methotrexate—hematologic cancer	1.95e-05	0.000124	CcSEcCtD
Propranolol—Nausea—Betamethasone—hematologic cancer	1.95e-05	0.000123	CcSEcCtD
Propranolol—Nausea—Dexamethasone—hematologic cancer	1.95e-05	0.000123	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—hematologic cancer	1.94e-05	0.000123	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.93e-05	0.000122	CcSEcCtD
Propranolol—Fatigue—Epirubicin—hematologic cancer	1.93e-05	0.000122	CcSEcCtD
Propranolol—Pain—Epirubicin—hematologic cancer	1.91e-05	0.000121	CcSEcCtD
Propranolol—Constipation—Epirubicin—hematologic cancer	1.91e-05	0.000121	CcSEcCtD
Propranolol—Urticaria—Methotrexate—hematologic cancer	1.9e-05	0.00012	CcSEcCtD
Propranolol—Dizziness—Prednisone—hematologic cancer	1.89e-05	0.00012	CcSEcCtD
Propranolol—Abdominal pain—Methotrexate—hematologic cancer	1.89e-05	0.00012	CcSEcCtD
Propranolol—Body temperature increased—Methotrexate—hematologic cancer	1.89e-05	0.00012	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—hematologic cancer	1.87e-05	0.000118	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—hematologic cancer	1.86e-05	0.000118	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—hematologic cancer	1.84e-05	0.000117	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—hematologic cancer	1.84e-05	0.000116	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—hematologic cancer	1.83e-05	0.000116	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—hematologic cancer	1.82e-05	0.000115	CcSEcCtD
Propranolol—Vomiting—Prednisone—hematologic cancer	1.82e-05	0.000115	CcSEcCtD
Propranolol—Rash—Prednisone—hematologic cancer	1.8e-05	0.000114	CcSEcCtD
Propranolol—Dermatitis—Prednisone—hematologic cancer	1.8e-05	0.000114	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—hematologic cancer	1.8e-05	0.000114	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.78e-05	0.000113	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—hematologic cancer	1.78e-05	0.000113	CcSEcCtD
Propranolol—Urticaria—Epirubicin—hematologic cancer	1.78e-05	0.000112	CcSEcCtD
Propranolol—Pain—Doxorubicin—hematologic cancer	1.77e-05	0.000112	CcSEcCtD
Propranolol—Constipation—Doxorubicin—hematologic cancer	1.77e-05	0.000112	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—hematologic cancer	1.77e-05	0.000112	CcSEcCtD
Propranolol—Abdominal pain—Epirubicin—hematologic cancer	1.77e-05	0.000112	CcSEcCtD
Propranolol—Hypersensitivity—Methotrexate—hematologic cancer	1.76e-05	0.000111	CcSEcCtD
Propranolol—Asthenia—Methotrexate—hematologic cancer	1.71e-05	0.000109	CcSEcCtD
Propranolol—Nausea—Prednisone—hematologic cancer	1.7e-05	0.000108	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.69e-05	0.000107	CcSEcCtD
Propranolol—Hypersensitivity—Epirubicin—hematologic cancer	1.65e-05	0.000104	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—hematologic cancer	1.64e-05	0.000104	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—hematologic cancer	1.63e-05	0.000104	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—hematologic cancer	1.63e-05	0.000104	CcSEcCtD
Propranolol—Diarrhoea—Methotrexate—hematologic cancer	1.63e-05	0.000104	CcSEcCtD
Propranolol—CYP1A1—lymph node—hematologic cancer	1.63e-05	0.0178	CbGeAlD
Propranolol—CYP2D6—testis—hematologic cancer	1.62e-05	0.0177	CbGeAlD
Propranolol—ABCB1—gonad—hematologic cancer	1.62e-05	0.0176	CbGeAlD
Propranolol—Asthenia—Epirubicin—hematologic cancer	1.6e-05	0.000102	CcSEcCtD
Propranolol—Dizziness—Methotrexate—hematologic cancer	1.58e-05	0.0001	CcSEcCtD
Propranolol—Diarrhoea—Epirubicin—hematologic cancer	1.53e-05	9.69e-05	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—hematologic cancer	1.52e-05	9.65e-05	CcSEcCtD
Propranolol—Vomiting—Methotrexate—hematologic cancer	1.52e-05	9.62e-05	CcSEcCtD
Propranolol—Rash—Methotrexate—hematologic cancer	1.51e-05	9.54e-05	CcSEcCtD
Propranolol—Dermatitis—Methotrexate—hematologic cancer	1.5e-05	9.53e-05	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—hematologic cancer	1.48e-05	9.4e-05	CcSEcCtD
Propranolol—Dizziness—Epirubicin—hematologic cancer	1.48e-05	9.36e-05	CcSEcCtD
Propranolol—Vomiting—Epirubicin—hematologic cancer	1.42e-05	9e-05	CcSEcCtD
Propranolol—Nausea—Methotrexate—hematologic cancer	1.42e-05	8.99e-05	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—hematologic cancer	1.41e-05	8.96e-05	CcSEcCtD
Propranolol—Rash—Epirubicin—hematologic cancer	1.41e-05	8.93e-05	CcSEcCtD
Propranolol—ABCB1—blood—hematologic cancer	1.41e-05	0.0154	CbGeAlD
Propranolol—Dermatitis—Epirubicin—hematologic cancer	1.41e-05	8.92e-05	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—hematologic cancer	1.37e-05	8.66e-05	CcSEcCtD
Propranolol—ABCB1—bone marrow—hematologic cancer	1.36e-05	0.0149	CbGeAlD
Propranolol—Nausea—Epirubicin—hematologic cancer	1.33e-05	8.41e-05	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—hematologic cancer	1.31e-05	8.33e-05	CcSEcCtD
Propranolol—Rash—Doxorubicin—hematologic cancer	1.3e-05	8.26e-05	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—hematologic cancer	1.3e-05	8.25e-05	CcSEcCtD
Propranolol—ABCB1—lung—hematologic cancer	1.23e-05	0.0135	CbGeAlD
Propranolol—Nausea—Doxorubicin—hematologic cancer	1.23e-05	7.78e-05	CcSEcCtD
Propranolol—ABCB1—testis—hematologic cancer	1.16e-05	0.0127	CbGeAlD
Propranolol—ABCB1—lymph node—hematologic cancer	8.44e-06	0.00922	CbGeAlD
Propranolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	2.27e-06	4.08e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CCND1—hematologic cancer	2.26e-06	4.06e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	2.26e-06	4.06e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	2.26e-06	4.05e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—JUN—hematologic cancer	2.26e-06	4.05e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTP1—hematologic cancer	2.25e-06	4.05e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTM1—hematologic cancer	2.25e-06	4.04e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NCOR1—hematologic cancer	2.25e-06	4.04e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KRAS—hematologic cancer	2.25e-06	4.04e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	2.24e-06	4.02e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	2.24e-06	4.01e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MTR—hematologic cancer	2.24e-06	4.01e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCG2—hematologic cancer	2.24e-06	4.01e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAP2K1—hematologic cancer	2.22e-06	3.99e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	2.21e-06	3.97e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	2.21e-06	3.97e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CD—hematologic cancer	2.21e-06	3.96e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NCOR1—hematologic cancer	2.2e-06	3.95e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTM1—hematologic cancer	2.2e-06	3.95e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ENO2—hematologic cancer	2.19e-06	3.93e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—CDKN1A—hematologic cancer	2.19e-06	3.93e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—PIK3CA—hematologic cancer	2.19e-06	3.92e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PTEN—hematologic cancer	2.18e-06	3.92e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	2.18e-06	3.91e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYCS—hematologic cancer	2.17e-06	3.89e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CG—hematologic cancer	2.16e-06	3.88e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	2.16e-06	3.88e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—KRAS—hematologic cancer	2.16e-06	3.88e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—HSP90AA1—hematologic cancer	2.15e-06	3.86e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.14e-06	3.85e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK8—hematologic cancer	2.14e-06	3.83e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.13e-06	3.83e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	2.13e-06	3.83e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—AKT1—hematologic cancer	2.13e-06	3.82e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.13e-06	3.82e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	2.12e-06	3.8e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—FGF2—hematologic cancer	2.11e-06	3.79e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3R1—hematologic cancer	2.08e-06	3.74e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EP300—hematologic cancer	2.08e-06	3.74e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—SDC1—hematologic cancer	2.08e-06	3.73e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	2.08e-06	3.73e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	2.07e-06	3.72e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.07e-06	3.72e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.07e-06	3.72e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	2.07e-06	3.71e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—PIK3CA—hematologic cancer	2.07e-06	3.71e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CG—hematologic cancer	2.04e-06	3.67e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	2.03e-06	3.65e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—JAK2—hematologic cancer	2.03e-06	3.64e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SRC—hematologic cancer	2.02e-06	3.63e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	2.02e-06	3.63e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	2.01e-06	3.61e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	2.01e-06	3.61e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CREBBP—hematologic cancer	2.01e-06	3.6e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—hematologic cancer	2e-06	3.59e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—MTHFR—hematologic cancer	1.99e-06	3.57e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—PIK3CA—hematologic cancer	1.99e-06	3.56e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTEN—hematologic cancer	1.98e-06	3.56e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTEN—hematologic cancer	1.98e-06	3.55e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MDM2—hematologic cancer	1.98e-06	3.55e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—VEGFA—hematologic cancer	1.97e-06	3.54e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	1.97e-06	3.53e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	1.97e-06	3.53e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—STAT3—hematologic cancer	1.95e-06	3.5e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—NRAS—hematologic cancer	1.95e-06	3.5e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—MTHFR—hematologic cancer	1.94e-06	3.49e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	1.94e-06	3.48e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CB—hematologic cancer	1.92e-06	3.45e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MTOR—hematologic cancer	1.92e-06	3.45e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	1.92e-06	3.45e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—HRAS—hematologic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTP1—hematologic cancer	1.91e-06	3.43e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CD—hematologic cancer	1.9e-06	3.41e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CREBBP—hematologic cancer	1.89e-06	3.4e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—EP300—hematologic cancer	1.89e-06	3.39e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	1.89e-06	3.39e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—EP300—hematologic cancer	1.89e-06	3.39e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	1.88e-06	3.37e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ALB—hematologic cancer	1.88e-06	3.37e-05	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	1.87e-06	3.35e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MAPK3—hematologic cancer	1.87e-06	3.35e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	1.85e-06	3.32e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	1.85e-06	3.32e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	1.85e-06	3.32e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	1.85e-06	3.31e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	1.84e-06	3.3e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—HRAS—hematologic cancer	1.84e-06	3.3e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—MTHFR—hematologic cancer	1.83e-06	3.29e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL6—hematologic cancer	1.83e-06	3.28e-05	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	1.83e-06	3.28e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MYC—hematologic cancer	1.81e-06	3.26e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	1.81e-06	3.25e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TGFB1—hematologic cancer	1.81e-06	3.25e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ABCB1—hematologic cancer	1.81e-06	3.24e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	1.81e-06	3.24e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1B—hematologic cancer	1.81e-06	3.24e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	1.8e-06	3.23e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	1.8e-06	3.23e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	1.8e-06	3.23e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CD—hematologic cancer	1.8e-06	3.22e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3R1—hematologic cancer	1.8e-06	3.22e-05	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—AKT1—hematologic cancer	1.79e-06	3.21e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ALB—hematologic cancer	1.77e-06	3.18e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CASP3—hematologic cancer	1.77e-06	3.18e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL2—hematologic cancer	1.77e-06	3.17e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NQO1—hematologic cancer	1.77e-06	3.17e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CD44—hematologic cancer	1.77e-06	3.17e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	1.76e-06	3.16e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL6—hematologic cancer	1.76e-06	3.16e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	1.76e-06	3.16e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NCOR1—hematologic cancer	1.75e-06	3.15e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTM1—hematologic cancer	1.75e-06	3.15e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.75e-06	3.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	1.74e-06	3.13e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	1.74e-06	3.12e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CCND1—hematologic cancer	1.72e-06	3.09e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—JUN—hematologic cancer	1.72e-06	3.09e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	1.7e-06	3.06e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	1.7e-06	3.05e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	1.7e-06	3.05e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3R1—hematologic cancer	1.7e-06	3.04e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	1.7e-06	3.04e-05	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—AKT1—hematologic cancer	1.69e-06	3.03e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KRAS—hematologic cancer	1.68e-06	3.01e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CG—hematologic cancer	1.67e-06	3e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CYCS—hematologic cancer	1.67e-06	3e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—CDKN1A—hematologic cancer	1.67e-06	2.99e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	1.66e-06	2.99e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PTEN—hematologic cancer	1.66e-06	2.98e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	1.66e-06	2.98e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	1.66e-06	2.98e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	1.66e-06	2.98e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CB—hematologic cancer	1.66e-06	2.98e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CG—hematologic cancer	1.63e-06	2.93e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK8—hematologic cancer	1.63e-06	2.92e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—AKT1—hematologic cancer	1.62e-06	2.91e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	1.62e-06	2.91e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	1.61e-06	2.89e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EP300—hematologic cancer	1.59e-06	2.85e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	1.58e-06	2.83e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	1.57e-06	2.82e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CB—hematologic cancer	1.57e-06	2.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	1.55e-06	2.79e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	1.55e-06	2.78e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—MTHFR—hematologic cancer	1.55e-06	2.78e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CREBBP—hematologic cancer	1.55e-06	2.78e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SRC—hematologic cancer	1.54e-06	2.77e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—PIK3CA—hematologic cancer	1.54e-06	2.76e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CG—hematologic cancer	1.54e-06	2.76e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	1.54e-06	2.76e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	1.52e-06	2.73e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	1.52e-06	2.72e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CREBBP—hematologic cancer	1.51e-06	2.72e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—VEGFA—hematologic cancer	1.5e-06	2.7e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—hematologic cancer	1.49e-06	2.67e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—STAT3—hematologic cancer	1.49e-06	2.67e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	1.49e-06	2.67e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—NRAS—hematologic cancer	1.48e-06	2.66e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTP1—hematologic cancer	1.47e-06	2.65e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CD—hematologic cancer	1.47e-06	2.64e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	1.45e-06	2.61e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ALB—hematologic cancer	1.45e-06	2.6e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	1.44e-06	2.59e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	1.44e-06	2.59e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.43e-06	2.58e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTEN—hematologic cancer	1.43e-06	2.57e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.43e-06	2.56e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—HRAS—hematologic cancer	1.42e-06	2.56e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MAPK3—hematologic cancer	1.42e-06	2.55e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ALB—hematologic cancer	1.42e-06	2.54e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	1.41e-06	2.54e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	1.41e-06	2.53e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PIK3CA—hematologic cancer	1.4e-06	2.51e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PIK3CA—hematologic cancer	1.4e-06	2.51e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.4e-06	2.5e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3R1—hematologic cancer	1.39e-06	2.49e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MYC—hematologic cancer	1.38e-06	2.48e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TGFB1—hematologic cancer	1.38e-06	2.47e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	1.37e-06	2.45e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—EP300—hematologic cancer	1.37e-06	2.45e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL6—hematologic cancer	1.36e-06	2.45e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.36e-06	2.43e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.35e-06	2.43e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.35e-06	2.43e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTEN—hematologic cancer	1.35e-06	2.43e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.35e-06	2.43e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	1.33e-06	2.4e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ALB—hematologic cancer	1.33e-06	2.4e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	1.31e-06	2.34e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CG—hematologic cancer	1.3e-06	2.34e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—EP300—hematologic cancer	1.29e-06	2.32e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CB—hematologic cancer	1.28e-06	2.3e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.28e-06	2.29e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KRAS—hematologic cancer	1.28e-06	2.29e-05	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—AKT1—hematologic cancer	1.26e-06	2.26e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.25e-06	2.24e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	1.23e-06	2.2e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CREBBP—hematologic cancer	1.21e-06	2.17e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	1.2e-06	2.15e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.2e-06	2.15e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	1.19e-06	2.13e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.18e-06	2.12e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—PIK3CA—hematologic cancer	1.17e-06	2.11e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	1.16e-06	2.08e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CD—hematologic cancer	1.15e-06	2.06e-05	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—AKT1—hematologic cancer	1.14e-06	2.05e-05	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—AKT1—hematologic cancer	1.14e-06	2.05e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—hematologic cancer	1.13e-06	2.04e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	1.13e-06	2.04e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ALB—hematologic cancer	1.13e-06	2.03e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	1.11e-06	1.99e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTEN—hematologic cancer	1.11e-06	1.99e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	1.09e-06	1.95e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—HRAS—hematologic cancer	1.09e-06	1.95e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3R1—hematologic cancer	1.08e-06	1.94e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTEN—hematologic cancer	1.08e-06	1.94e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	1.06e-06	1.91e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—EP300—hematologic cancer	1.06e-06	1.9e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL6—hematologic cancer	1.04e-06	1.86e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—EP300—hematologic cancer	1.03e-06	1.85e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTEN—hematologic cancer	1.02e-06	1.83e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PIK3CA—hematologic cancer	1.01e-06	1.81e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.01e-06	1.81e-05	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	1e-06	1.8e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CB—hematologic cancer	9.98e-07	1.79e-05	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	9.8e-07	1.76e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—EP300—hematologic cancer	9.71e-07	1.74e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—AKT1—hematologic cancer	9.58e-07	1.72e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PIK3CA—hematologic cancer	9.55e-07	1.71e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—CREBBP—hematologic cancer	9.32e-07	1.67e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CD—hematologic cancer	8.84e-07	1.59e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ALB—hematologic cancer	8.73e-07	1.57e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTEN—hematologic cancer	8.63e-07	1.55e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3R1—hematologic cancer	8.35e-07	1.5e-05	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—AKT1—hematologic cancer	8.25e-07	1.48e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—EP300—hematologic cancer	8.23e-07	1.48e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PIK3CA—hematologic cancer	7.81e-07	1.4e-05	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—AKT1—hematologic cancer	7.8e-07	1.4e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CB—hematologic cancer	7.71e-07	1.38e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PIK3CA—hematologic cancer	7.62e-07	1.37e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PIK3CA—hematologic cancer	7.19e-07	1.29e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTEN—hematologic cancer	6.66e-07	1.2e-05	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—AKT1—hematologic cancer	6.38e-07	1.15e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—EP300—hematologic cancer	6.35e-07	1.14e-05	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—AKT1—hematologic cancer	6.23e-07	1.12e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PIK3CA—hematologic cancer	6.09e-07	1.09e-05	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—AKT1—hematologic cancer	5.87e-07	1.05e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—AKT1—hematologic cancer	4.97e-07	8.92e-06	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PIK3CA—hematologic cancer	4.7e-07	8.43e-06	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—AKT1—hematologic cancer	3.84e-07	6.89e-06	CbGpPWpGaD
